Industry News
Biotechnology Industry News
Alector Therapeutics is shelving a…
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). To pivot away from latozinemab, the Bay Area biotech is laying
Sanofi’s $1.7 billion rare…
Sanofi’s $1.7 billion rare disease bet has delivered a phase 2 win. Efdoralprin alfa beat the standard of care on primary and key secondary endpoints, positioning the drugmaker to talk to regulators about the next
Ipsen is acquiring next-gen…
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy in a deal worth up to 1 billion euros (about $1.16 billion).
Takeda is paying Innovent…
Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes $10.2 billion in milestones, puts the biologics at the center of Takeda’s efforts to establish growth drivers
Terns Pharmaceuticals has shelved…
Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability that fell short of expectations and evidence the asset causes liver injuries.
Five years after launching one of…
Five years after launching one of the most promising generative biology drug discovery companies, Generate Biomedicines, venture capital powerhouse Flagship Pioneering has brought a generative chemistry drug discovery company out of stealth, supporting Expedition Medicines
Electra Therapeutics is…
Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate.
With $70 million and a phase 2…
With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the treatment of rheumatoid arthritis.
“We need to pick a lane here as…
“We need to pick a lane here as a country. Which one do we care more about? Proving survival, which means no crossover; or getting U.S. participation, where crossover is a pretty important incentive,” Eli
GSK and Spero Therapeutics have…
GSK and Spero Therapeutics have shared phase 3 results on their antibiotic candidate, revealing that the oral therapy closely matched the intravenous incumbent in a trial that could support filings for approval.
Neuphoria Therapeutics’ lead…
Neuphoria Therapeutics’ lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the biotech to discontinue the program and launch a strategic review of its business.
Galapagos is planning to wind down…
Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months.
After rejecting Replimune’s…
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval application.
The U.S. private equity market is…
The U.S. private equity market is showing signs of recovery, with strong deal activity and lower interest rates driving optimism, though exit and fundraising challenges remain.
As scientific disinformation…
As scientific disinformation skyrockets, the Biotechnology Innovation Organization (BIO)—the world’s largest biotech trade association—is aiming to set the record straight on vaccines, rolling out a campaign highlighting the unmistakable value immunizations have on public health
BioNTech is not planning further…
BioNTech is not planning further trials of its BNT111 vaccine candidate in a specific late-stage refractory melanoma setting, a company spokesperson said.
Daiichi Sankyo and Merck & Co….
Daiichi Sankyo and Merck & Co. have reported midphase ovarian cancer data, clearing the partners to advance the antibody-drug conjugate into the phase 3 part of the trial.
Roche is forging ahead with plans…
Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials.
From Roche’s $1.4 billion…
From Roche’s $1.4 billion licensing deal to AstraZeneca’s presidential symposium and an avalanche of clinical readouts, antibody-drug conjugates (ADCs) dominated Europe’s leading cancer conference over the weekend.
The company believes the data for…
The company believes the data for zanzalintinib validate its hopes of having another “franchise molecule” on its hands.